Brainsway Ltd. (TASE:BRIN) has obtained positive final results of its study to test the effect of its Deep TMS (transcanial magnetic stimulation) on blepharospasm, an abnormal spasm or twitching of the eyelid. The study found that Deep TMS was safe and had an immediate improvement in the disease.
Brainsway is headed by CEO Uzi Sofer. The Deep TMS technology was developed by Dr. Abraham Zangen and Dr. Yiftach Roth, both of who have worked at the US National Institutes of Health (NIH). Founded in 2003, the company has marketing approval for Deep TMS to treat depression, manic depression, and schizophrenia in Europe, and is conducting trials for applying for marketing approval in the US.
The blepharospasm study was conducted at the NIH unit National Institute of Neurological Disorders and Stroke by Dr. Mark Hallett. The patients were examined immediately after low-frequency Deep TMS treatments and an hour afterwards. The tests included the usual measures for assessing blepharospasm. The researchers cautioned that the study only examined the immediate effects following a single treatment, and that in view of the positive results, a longer study that includes repeat treatments to test the clinical results should be conducted.
Brainsway's share price rose 3.9% in morning trading to NIS 8.85, giving a market cap of NIS 363 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 24, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010